Clinical Trials - Visterra

Our desire to help patients drives everything we do at Visterra.

Clinical trials – research studies testing our therapeutic candidates in healthy subjects and patients – play a critically important part in developing our therapies. We design and run innovative and nimble pre-clinical studies and early phase clinical trials to answer critical questions about safety, tolerability, dosing regimen, pharmacokinetics, pharmacodynamics, biomarkers, and efficacy. We are thankful for and inspired by the volunteers and patients who participate in our trials.

Information about currently recruiting clinical trials of our therapeutic candidates is available below.

INDICATION

PROGRAM

NAME

TRIAL NUMBER

INDICATION

IgA nephropathy

PROGRAM

Sibeprenlimab (VIS649)

NAME

VISionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN)

TRIAL NUMBER

NCT05248646

INDICATION

Autoimmune Diseases

PROGRAM

VIS171

NAME

A Study to Evaluate the Safety, PK and PD of VIS171 in Participants (Healthy and With Autoimmune Disease)

TRIAL NUMBER

NCT05418101

EXPANDED ACCESS POLICY

We currently do not accept or grant requests to use our investigational drugs outside of clinical trials. Such “expanded” access could negatively impact or delay our clinical development efforts by, for example, compromising clinical trial results, interfering with or delaying regulatory filings and adversely impacting the manufacturing and supply of investigational drug product.

We believe clinical trials are the most appropriate way to provide access to our investigational drugs to patients as quickly and safely as possible. If you have questions about this policy or would like information about our clinical trials, please contact privacy@visterrainc.com.

We typically respond acknowledging receipt within five business days. You may also find information about our clinical trials at www.clinicaltrials.gov. We may revise this policy and website at any time without notice.